Questions? Call 1-877-357-9661
Pimecrolimus for Veterinary Use
by Barbara Forney, VMD
Pimecrolimus is an immunomodulatory drug from the same family as tacrolimus. These drugs were originally developed specifically for the treatment of inflammatory skin disease in people. The mechanism of action for both pimecrolimus and tacrolimus is through the inhibition of calcium dependent pathways that effect the enzymatic action of calcineuron. This, in turn, block the proliferation of T lymphocytes and cytotoxic cells.
Pimecrolimus has significant anti-inflammatory and immunmodulatory properties, veterinary use of both pimecrolimus and tacrolimus is primarily for ketratoconjunctivitis sicca (KCS) in dogs and cats, and immune-mediated dermatologic diseases.
There is a topical pimecrolimus cream that is approved for human use called Elidel ®
. It is used for the treatment of atopic dermatities in humans.
Dogs and Cats
Keratoconjunctivitis sicca due to decreased tear production is primarily an immune-mediated disease of the lacrimal glands. It is seen more commonly in dogs than in cats. Cyclosporine has been the standard drug for the treatment of keratoconjunctivitis sicca treatment, although not all animals respond adequately. Ophthalmic pimecrolimus is considerably more effective than cyclosporine in decreasing clinic signs due to inflammation, and equally as effective in increasing tear production. Animals with immune-mediated KCS will need to be on treatment for the rest of their life.
- Pimecrolimus is very well tolerated in the ophthalmic treatment of KCS. Animals irritated by ophthalmic tacrolimus may tolerate ophthalmic pimecrolimus.
- Pimecrolimus is generally well tolerated when used for the localized topical treatment of dermatologic problems. Skin irritation is the most common side effect cited in the human literature.
- GI symptoms may be encountered from ingestion of the topical ointment (licking).
- Only topical or ophthalmic use of pimecrolimus are currently recommended. Reports in the human literature would indicated that there is very little systemic absorption of topical pimecrolimus.
- No information regarding drug interaction was found.
- No information regarding overdosage was found.
About the Author
Dr. Barbara Forney is a veterinary practitioner in Chester County, Pennsylvania. She has a master's degree in animal science from the University of Delaware and graduated from the University of Pennsylvania School of Veterinary Medicine in 1982.
She began to develop her interest in client education and medical writing in 1997. Recent publications include portions of The Pill Book Guide to Medication for Your Dog and Cat, and most recently Understanding Equine Medications published by the Bloodhorse.
Dr. Forney is an FEI veterinarian and an active member of the AAEP, AVMA, and AMWA.
The information contained on this site is general in nature and is intended for use as an informational aid. It does not cover all possible uses, actions, precautions, side effects, or interactions of the products shown, nor is the information intended as medical advice or diagnosis for individual health problems or for making an evaluation as to the risks and benefits of using a particular product. You should consult your doctor about diagnosis and treatment of any health problems. Information and statements have not been evaluated by the Food and Drug Administration ("FDA"), nor has the FDA approved the products to diagnose, cure or prevent disease.
Wedgewood Pharmacy's compounded veterinary preparations are not intended for use in food and food-producing animals.